Multiple sclerosis (MS), in which demyelination of the central nervous system (CNS) is a hallmark characteristic, is generally considered to be an autoimmune disease. However, neither the cause of MS nor triggers for developing the disease are well understood.

Charles River conducts contract studies in established animal models of MS to test the efficacy of novel therapeutics:

We have answered some frequently asked questions about our MS models.

You may also be interested in...

Imaging Services

Our range of imaging modalities can dramatically increase the efficiency and significantly enhance the value of your in vivo study.

Biomarker Services

We can support your drug discovery pipeline by providing biomarker analysis in a non-GxP environment.

Webinar Replay

With a focus on models that reflect the inflammation and demyelination process, this webinar examines those most useful in MS research and how phenotype, biomarkers and imaging can impact the quality of your studies.